Targeting Protein Kinases and Epigenetic Control As Combinatorial Therapy Options for Advanced Prostate Cancer Treatment

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2022 Mar 26

PMID 35335890

Authors

Soghra Bagheri

Mahdie Rahban

Fatemeh Bostanian

Fatemeh Esmaeilzadeh

Arash Bagherabadi

Samaneh Zolghadri

Agata Stanek

Affiliations

Soon will be listed here.

Abstract

Prostate cancer (PC), the fifth leading cause of cancer-related mortality worldwide, is known as metastatic bone cancer when it spreads to the bone. Although there is still no effective treatment for advanced/metastatic PC, awareness of the molecular events that contribute to PC progression has opened up opportunities and raised hopes for the development of new treatment strategies. Androgen deprivation and androgen-receptor-targeting therapies are two gold standard treatments for metastatic PC. However, acquired resistance to these treatments is a crucial challenge. Due to the role of protein kinases (PKs) in the growth, proliferation, and metastases of prostatic tumors, combinatorial therapy by PK inhibitors may help pave the way for metastatic PC treatment. Additionally, PC is known to have epigenetic involvement. Thus, understanding epigenetic pathways can help adopt another combinatorial treatment strategy. In this study, we reviewed the PKs that promote PC to advanced stages. We also summarized some PK inhibitors that may be used to treat advanced PC and we discussed the importance of epigenetic control in this cancer. We hope the information presented in this article will contribute to finding an effective treatment for the management of advanced PC.

Citing Articles

Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatment.

Rahban M, Joushi S, Bashiri H, Saso L, Sheibani V Front Chem. 2024; 11:1325214.

PMID: 38264122 PMC: 10804459. DOI: 10.3389/fchem.2023.1325214.

Small Molecule Targeting Immune Cells: A Novel Approach for Cancer Treatment.

Singh S, Barik D, Arukha A, Prasad S, Mohapatra I, Singh A Biomedicines. 2023; 11(10).

PMID: 37892995 PMC: 10604364. DOI: 10.3390/biomedicines11102621.

Unveiling Novel Avenues in mTOR-Targeted Therapeutics: Advancements in Glioblastoma Treatment.

Singh S, Barik D, Lawrie K, Mohapatra I, Prasad S, Naqvi A Int J Mol Sci. 2023; 24(19).

PMID: 37834408 PMC: 10573615. DOI: 10.3390/ijms241914960.

Targeted EGFR Nanotherapy in Non-Small Cell Lung Cancer.

Crintea A, Constantin A, Motofelea A, Crivii C, Velescu M, Coseriu R J Funct Biomater. 2023; 14(9).

PMID: 37754880 PMC: 10532491. DOI: 10.3390/jfb14090466.

Regulation of Kinase Signaling Pathways by α6β4-Integrins and Plectin in Prostate Cancer.

Koivusalo S, Schmidt A, Manninen A, Wenta T Cancers (Basel). 2023; 15(1).

PMID: 36612146 PMC: 9818203. DOI: 10.3390/cancers15010149.

References

Giannakouros T, Nikolakaki E, Mylonis I, Georgatsou E . Serine-arginine protein kinases: a small protein kinase family with a large cellular presence. FEBS J. 2011; 278(4):570-86. DOI: 10.1111/j.1742-4658.2010.07987.x. View

Hanks S, Hunter T . Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 1995; 9(8):576-96. View

Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J . Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5):1215-1228. PMC: 4484602. DOI: 10.1016/j.cell.2015.05.001. View

Boly R, Gras T, Lamkami T, Guissou P, Serteyn D, Kiss R . Quercetin inhibits a large panel of kinases implicated in cancer cell biology. Int J Oncol. 2011; 38(3):833-42. DOI: 10.3892/ijo.2010.890. View

Zhang C, Engqvist-Goldstein A, Carreno S, Owen D, Smythe E, Drubin D . Multiple roles for cyclin G-associated kinase in clathrin-mediated sorting events. Traffic. 2005; 6(12):1103-13. DOI: 10.1111/j.1600-0854.2005.00346.x. View

Patel R, Rupani R, Impreso S, Lui A, Patel N . Role of alternatively spliced, pro-survival Protein Kinase C delta VIII (PKCδVIII) in ovarian cancer. FASEB Bioadv. 2022; 4(4):235-253. PMC: 8984081. DOI: 10.1096/fba.2021-00090. View

Shukla S, Bhaskaran N, MacLennan G, Gupta S . Deregulation of FoxO3a accelerates prostate cancer progression in TRAMP mice. Prostate. 2013; 73(14):1507-17. PMC: 4018753. DOI: 10.1002/pros.22698. View

de Bono J, De Giorgi U, Nava Rodrigues D, Massard C, Bracarda S, Font A . Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss. Clin Cancer Res. 2018; 25(3):928-936. DOI: 10.1158/1078-0432.CCR-18-0981. View

Fabian M, Biggs 3rd W, Treiber D, Atteridge C, Azimioara M, Benedetti M . A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005; 23(3):329-36. DOI: 10.1038/nbt1068. View

10.

Smidova V, Michalek P, Goliasova Z, Eckschlager T, Hodek P, Adam V . Nanomedicine of tyrosine kinase inhibitors. Theranostics. 2021; 11(4):1546-1567. PMC: 7778595. DOI: 10.7150/thno.48662. View

11.

Kim J, Banerjee T, Vinckevicius A, Luo Q, Parker J, Baker M . A role for WDR5 in integrating threonine 11 phosphorylation to lysine 4 methylation on histone H3 during androgen signaling and in prostate cancer. Mol Cell. 2014; 54(4):613-25. PMC: 4075454. DOI: 10.1016/j.molcel.2014.03.043. View

12.

Mavrou A, Brakspear K, Hamdollah-Zadeh M, Damodaran G, Babaei-Jadidi R, Oxley J . Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer. Oncogene. 2014; 34(33):4311-9. PMC: 4351909. DOI: 10.1038/onc.2014.360. View

13.

Bullock A, Das S, Debreczeni J, Rellos P, Fedorov O, Niesen F . Kinase domain insertions define distinct roles of CLK kinases in SR protein phosphorylation. Structure. 2009; 17(3):352-62. PMC: 2667211. DOI: 10.1016/j.str.2008.12.023. View

14.

Eder I, Egger M, Neuwirt H, Seifarth C, Maddalo D, Desiniotis A . Enhanced inhibition of prostate tumor growth by dual targeting the androgen receptor and the regulatory subunit type iα of protein kinase a in vivo. Int J Mol Sci. 2013; 14(6):11942-62. PMC: 3709765. DOI: 10.3390/ijms140611942. View

15.

Valk-Lingbeek M, Bruggeman S, van Lohuizen M . Stem cells and cancer; the polycomb connection. Cell. 2004; 118(4):409-18. DOI: 10.1016/j.cell.2004.08.005. View

16.

Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S . The protein kinase complement of the human genome. Science. 2002; 298(5600):1912-34. DOI: 10.1126/science.1075762. View

17.

Giguere V . DNA-PK, Nuclear mTOR, and the Androgen Pathway in Prostate Cancer. Trends Cancer. 2020; 6(4):337-347. DOI: 10.1016/j.trecan.2020.01.015. View

18.

Ponguta L, Gregory C, French F, Wilson E . Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer. J Biol Chem. 2008; 283(30):20989-1001. PMC: 2475695. DOI: 10.1074/jbc.M802392200. View

19.

Wang X, Sun B, Wei L, Jian X, Shan K, He Q . Cholesterol and saturated fatty acids synergistically promote the malignant progression of prostate cancer. Neoplasia. 2021; 24(2):86-97. PMC: 8718564. DOI: 10.1016/j.neo.2021.11.004. View

20.

Moradpour Z, Barghi L . Novel Approaches for Efficient Delivery of Tyrosine Kinase Inhibitors. J Pharm Pharm Sci. 2019; 22(1):37-48. DOI: 10.18433/jpps29891. View